The U.S. Food and Drug Administration (FDA) has approved the expansion of Abiomed’s Impella 5.0 and Impella LD premarket approval (PMA) labeling for the treatment of cardiogenic shock. The expansion extends the duration of support for each pump from 6 days to 14 days.

May 14, 2019 – The first prospective, multicenter, randomized, controlled trial to compare conventional pulmonary vein isolation (PVI) to FIRM-guided rotor ablation followed by PVI in persistent atrial fibrillation (AF) patients failed to provide evidence for Abbott FIRM plus PVI was superiority at 3-12 months.

The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus statement reflecting a worldwide updated review of the indications, techniques and outcomes of catheter ablation of ventricular arrhythmias (VAs). The expert consensus statement was presented at Heart Rhythm 2019, the HRS’s 40th Annual Scientific Sessions, May 8-11 in San Francisco.

The Heart Rhythm Society (HRS) released a first-of-its-kind consensus statement with guidance on the evaluation and management of arrhythmogenic cardiomyopathy (ACM), including findings on genetics and disease mechanisms. Recommendations included in the 2019 HRS Expert Consensus Statement on Evaluation, Risk Stratification, and Management of Arrhythmogenic Cardiomyopathy were presented at Heart Rhythm 2019, the HRS’s 40th Annual Scientific Sessions, May 8-11 in San Francisco.

May 14, 2019 – Results from new research show that passengers with cardiac implantable electronic devices (CIEDs), such as pacemakers or implantable cardioverter defibrillators (ICDs), can safely travel through airport security checkpoint scanners. This is the first study to look at the relationship between body scanners and the impact on functionality of devices.

International Academy of Cardiology World Congress on Heart Disease

The Congress will provide the opportunity for a comprehensive overview of the latest research developments in Cardiovascular Medicine, primarily in the areas of Molecular and Cellular Cardiology, Genetics of Heart Disease, Cardiac Imaging, Coronary Artery Disease, Peripheral Arterial Disease, Interventional Cardiology, Lipoprotein Disorders, Hypertension, Metabolic Syndrome, Diabetes Mellitus, Cardio-Oncology, Heart Failure, Valvular Heart Disease, Diseases of the Aorta, Cardiac Arrhythmias and Electrophysiology, Implantable Cardiac Pacemakers and Cardioverter-Defibrillators, Sudden Cardi

May 13, 2019 — Boston Scientific announced acute results from the UNTOUCHED study evaluating safety and efficacy of the Emblem subcutaneous implantable defibrillator (S-ICD) system for primary prevention of sudden cardiac death specifically in patients with a left ventricular ejection fraction (LVEF) ≤35 percent. This is the most common population to be indicated for ICD therapy.

May 13, 2019 – Results from a new survey are the first to report a large discrepancy in patient’s knowledge of their cardiac implantable electronic device (CIED). The study reviewed patients’ overall knowledge of data from their devices as well as their perceptions on what is most important. Participants in this study have a strong desire to better understand their device and its data, with more guidance on battery life as the most important aspect for patients.

May 13, 2019 – A first-in-human pilot study of Medtronic's investigational Extravascular Implantable Cardioverter Defibrillator (EV ICD) system showed it can be implanted with no major complications, and can sense, pace and defibrillate the heart. Results from the pilot study were presented during a late-breaking session at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Scientific Sessions.

May 13, 2019 — A randomized clinical trial effectively used nerve stimulation through an ear clip to reduce atrial fibrillation (AF) burden and showcases an emerging noninvasive treatment option for patients. The trial is the first to examine the effect of transcutaneous electrical vagus nerve stimulation on suppressing AF.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now